Campylobacter pylori is a gram negative spiral bacterium that produces a powerful urease that splits urea with the production of ammonia. By neutralising intragastric pH with ammonia C pylori is able to colonise the stomach and survive conditions unsuitable for other bacteria. We present a patient who illustrates the relation between C pylori and plasma gastrin concentration and whose duodenal ulcer disease was healed only after treatment was aimed at eradication of C pylori.

History

The patient was a 32 year old stocktaker. He gave a two year history of recurrent abdominal pain in the epigastrium and right upper quadrant. The pain was sharp, usually occurring between meals, and woke him in the early hours of the morning. He smoked 20 cigarettes daily and drank 10 units of alcohol each week. He had not taken aspirin or other non-steroidal anti-inflammatory drugs. Physical examination yielded normal results.

In May 1988 he had been prescribed a course of ranitidine 150 mg twice daily, and his symptoms were relieved within two days. Two months later, however, his symptoms recurred after stopping treatment, and endoscopy showed duodenal ulceration. Ranitidine was restarted and a repeat endoscopy after six weeks confirmed healing. He remained well taking a maintenance dose of ranitidine (150 mg nightly) until December 1988 when he suffered further symptoms.

Further endoscopy at this time confirmed the presence of duodenal ulcer disease. Multiple biopsy specimens were taken and showed C pylori and mild chronic gastritis (fig 1). A test for urease was done by placing two antral biopsy specimens in a solution of urea and phenol red (fig 2). The presence of C pylori was indicated by the change in colour from yellow to pink, signifying the hydrolysis of urea to ammonia by urease, with net production of alkali. Studies of acid secretion showed a high basal acid output of 10 mmol/h (normal <5 mmol/h) and a high pentagastrin-stimulated acid output of 46 mmol/h (normal <35 mmol/h). Basal plasma gastrin concentration was 20 pmol/l, and peak meal stimulated gastrin concentration was 100 pmol/l, which was above the normal range (<60 pmol/l) and typical of concentrations seen in duodenal ulcer disease.

Treatment was started to eradicate C pylori and consisted of metronidazole 400 mg thrice daily for two weeks and colloidal bismuth subcitrate (DeNol) 120 mg four times daily for four weeks. His symptoms completely resolved within one week, and one month later his ulcer had healed. Histological examination and repeat urease testing confirmed eradication of antral C pylori. His pentagastrin-stimulated acid output had also fallen to 25 mmol/h, and his peak meal stimulated gastrin concentration was 60 pmol/l. Six months later the patient was well without further treatment.

Comment

Patients with duodenal ulcer disease tend to have higher rates of acid secretion, whether stimulated by pentagastrin or by meals, as well as high plasma gastrin concentrations after meals. This is surprising because increased gastric acid should inhibit release of gastrin. Thus the hypergastrinaemia can be considered inappropriate, suggesting a failure of regulation of gastrin release from antral G cells. In support of this low intragastric pH has been shown to inhibit release of antral gastrin less effectively in patients with duodenal ulcer disease than in normal subjects.1 We wondered whether the powerful urease produced by C pylori may (through the local production of ammonia) increase the pH within the mucus layer that overlies the gastric antrum. The normal inhibition of gastrin by increased intraluminal acid would be impaired because the cells would see only the (falsely high) local pH. The persistently and inappropriately raised gastrin would not only increase the amount of acid secreted but also in time increase the acid-secreting fundic parietal cell mass.

We examined this hypothesis in a group of patients similar to the patient presented, all with active duodenal ulcer disease at endoscopy. In this study 25 of the 31 patients were positive for C pylori by the urease test performed on antral biopsy specimens. Peak pentagastrin-stimulated acid secretion was significantly

---

**FIG 1—Biopsy specimen of gastric antral mucosa (stained with haematoxylin and eosin), showing mild chronic gastritis and numerous spiral bacteria in crypt**

**FIG 2—Urease test for presence of C pylori. Two antral biopsy specimens are crushed in 0.5 ml of solution of urea (20 g/l), potassium dihydrogen orthophosphate (2 g/l), and phenol red (0.04 g/l) as indicator. Urease activity results in production of ammonia and colour change from yellow to pink**
higher in the patients positive for *C. pylori* than in those negative for it with duodenal ulcer disease. Furthermore, plasma gastrin concentrations after meals were more than twice those in the patients positive for *C. pylori* than in those negative for it.

Thus in *C. pylori* infection of the gastric antrum there is increased gastrin production. This increase is probably due to the local production of ammonia and resultant local changes in pH (fig 3).

**Discussion**

JC: This brings together several strands of evidence in relation to the aetiology of duodenal ulcer disease. The disease is believed to be the common end result of several different physiological abnormalities contributing to ulceration. This patient led us to question whether acid secretion and the role of *C. pylori* were independent risk factors for the disease or if there was a relation between them. If they were independent we would have expected to see similar acid secretion in patients positive and negative for urease (or perhaps even more acid in the patients negative for urease to cause ulceration in the absence of the organism). In fact we found increased acid secretion in patients infected with *C. pylori*, and this does fit in with the hypothesis presented.

CTD: Are you sure that the characteristics of the patients negative for *C. pylori* in your study were not radically different from those positive for it?

SL: The two groups were similar with respect to age, sex, and duration of disease.

SRB: There has been a considerable amount of work over the years showing clearly that patients with duodenal ulcer disease have a higher acid–gastrin product—that is, they have either higher acid output or higher gastrin, or both. Until now this has fitted uneasily with the observation that a high proportion of patients are infected with *C. pylori*, an organism that can reduce gastric acid. This new hypothesis would seem to overcome the apparent paradox nicely. Further proof will come from the study of the response to treatment infection with *C. pylori* in series of patients.

MSL: These organisms were described at the turn of the century and again more recently, but people have dismissed them because no one could believe that duodenal ulcer disease may be an infectious disease. A further point I would add in support of this hypothesis is that *C. pylori* is capable of producing high concentrations of urease.

NAW: *C. pylori* does not usually colonise the duodenal mucosa except when there is pyloric metaplasia, as seen in patients with duodenitis or duodenal ulcers.

Do your patients with antral *C. pylori* colonisation also show colonisation of these metaplastic areas in the duodenum, and if so do you think that a direct local toxic effect on the duodenum is possible through this mechanism?

JC: We have started to look at this, but this patient did not have a duodenal biopsy. I do not think our results refute the possibility that the position of the ulcer in the duodenum is in some way related to gastric metaplasia.

TMC: Marshall, who rekindled interest in *C. pylori* inoculated himself with the organism and showed that it could be passaged in that way. I wonder whether Koch's postulates may be applied here. Would it, for example, be possible to test definitively whether the organism induced the acid abnormalities and if so what was the time course from inoculation?

MSL: Of the two cases described in reports permanent self induced infection with *C. pylori* has occurred in both. Various animal models exist, but their applicability to humans with duodenal ulcer disease is questionable.

OMW: Much has been written about gastric urease. I think that the general view is that some of it is not bacterial. I wonder how the *C. pylori* story fits in with what is known about gastric urease.

JC: My understanding is that all gastric urease is attributable to *C. pylori*.

MBP: It should be fairly straightforward to resolve the urease question immunohistochemically. There must be antigenic differences between *C. pylori* urease and human urease in the stomach. This may also lead to a more sophisticated diagnostic quick test for the presence of *C. pylori* in the biopsy specimen.

HJFH: To pursue the question of infection. We have talked about *C. pylori* in the context of duodenal ulcer disease; the other role of *C. pylori* is in the development of acute and chronic gastritis, and this is where most studies have been done in volunteers. This produces a different disease, so it is not going to be possible to fulfil Koch's postulate for duodenal ulcer disease in this way. The patient and data presented raise intriguing questions about, for example, familial hypergastrinaemia and familial duodenal ulcers and to what extent these are going to be based on the absence or presence of genetically determined adherence factors that make infection and long term colonisation with these organisms more likely.

CTD: Viewed from the point of good clinical management of this common condition when should *C. pylori* be looked for and when is treatment with antibiotics indicated?

JC: The history of repeated relapses of duodenal ulcers after withdrawal of treatment with histamine-2 receptor antagonist should certainly prompt investigation for *C. pylori* and, if *C. pylori* is present, treatment with antibiotics. The test for urease on gastric biopsy specimens is fairly easy to perform and entails crushing two antral biopsy specimens in a solution of urea containing phenol red. A change in colour from yellow to pink indicates the presence of *C. pylori*. Testing for acid secretion is a simple procedure performed on an outpatient basis and is measured by continuous gastric aspiration followed by a test meal during which blood is taken for gastrin radioimmunoassay.